Kvartalsrapport (Q2)
5 dager siden
Ordredybde
Antall
Kjøp
386
Selg
Antall
53
Siste handler
| Tid | Pris | Antall | Kjøpere | Selger |
|---|---|---|---|---|
| - | - | - | - |
Høy
4,3VWAP
Lav
3,46OmsetningAntall
8,4 4 212 237
VWAP
Høy
4,3Lav
3,46OmsetningAntall
8,4 4 212 237
Meglerstatistikk
Fant ingen data
Selskapshendelser
| Kommende | |
|---|---|
Selskapskalender ikke tilgjengelig | |
| Historisk | ||
|---|---|---|
| 2025 Kvartalsrapport (Q2) | 14. aug. | |
| 2025 Generalforsamling | 20. juni | |
| 2025 Kvartalsrapport (Q1) | 9. mai | |
| 2025 Kvartalsrapport (Q1) | 8. mai | |
| 2024 Kvartalsrapport (Q4) | 21. mars |
Data hentes fra Morningstar, Quartr
Kunder besøkte også
Shareville
Bli med i samtalen på SharevilleEt fellesskap av investorer som deler innsikt og kunnskap i sine porteføljer.
Logg inn
4. aug.4. aug.🚀🚀🚀🚀🚀🚀🚀🚀 NEW YORK, Aug. 4, 2025 /CNW/ -- As America's population ages, chronic and rare diseases are emerging as a pressing healthcare challenge — one that disproportionately affects older adults. With more than 30 million Americans living with a rare disease, the need for accurate diagnoses and effective treatments is growing urgent. Many of these conditions remain without FDA-approved therapies, and symptoms in seniors are often misattributed to typical aging, leading to years-long diagnostic delays. Recognizing this crisis, the Trump administration's "Make America Healthy Again" initiatives have emphasized improving access to treatments and accelerating medical innovation. Advancing this mission, Soligenix Inc. (NASDAQ: SNGX) (Profile) is making strides with its HyBryte(TM) platform, a novel therapy aimed at treating cutaneous T-cell lymphoma (CTCL), a rare skin cancer that primarily affects older adults. With successful U.S.-based manufacturing of HyBryte's active ingredient now in place, Soligenix exemplifies the kind of domestic innovation poised to make a meaningful impact on this underserved patient population. The company is one of several impressive companies committed to making an impact in the pharmaceutical space,
30. jan.30. jan.January 14 Soligenix announced an interim update on the open-label, investigator-initiated study evaluating extended HyBryte – synthetic hypericin – treatment for up to 12 months in patients with early-stage cutaneous T-cell lymphoma, or CTCL. To date, nine patients have been enrolled and treated with HyBryte over a time period of up to 54 weeks. Patients have responded positively to HyBryte therapy, with over 70% already achieving “Treatment Success”, predefined as a greater than or equal to 50% improvement in the cumulative mCAILS score compared to Baseline. Of the five Treatment Successes, three were achieved within the first 12 weeks of treatment, with two patients achieving a “complete response” by 18 weeks. In addition, HyBryte appears to be safe and well tolerated in all patients. Dr. Kim, Lead Investigator of the FLASH2 study, stated, “In the first Phase 3 FLASH study, HyBryte was shown to be efficacious with a benign safety profile compared to the current therapies of steroids, chemotherapeutics and ultraviolet light in this chronic orphan disease…In our FDA-funded study, initial results evaluating the expanded use of HyBryte in a “real world” treatment setting remain very promising, further supporting and extending results from the previous positive Phase 2 and 3 clinical trials. We look forward to continuing to work with the FDA to complete this study while we participate in the confirmatory Phase 3 placebo-controlled FLASH2 study.”- 29. jan.29. jan.These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Phio Pharmaceuticals (PHIO), 39,675% surge in interest Eterna Therapeutics (ERNA), 11,117% surge in interest Salarius Pharmaceuticals (SLRX), 10,853% surge in interest Kairos Pharma (KAPA), 2,805% surge in interest Soligenix (SNGX), 1,913% surge in interest Silexion Therapeutics (SLXN), 1,717% surge in interest Azitra (AZTR), 1,645% surge in interest Black Diamond Therapeutics (BDTX), 1,315% surge in interest iBio (IBIO), 935% surge in interest GT Biopharma (GTBP), 900% surge in interest
Kommentarene ovenfor kommer fra brukere på Nordnets sosiale nettverk Shareville og er verken redigert eller forhåndsvist av Nordnet. De innebærer ikke at Nordnet gir investeringsråd eller investeringsanbefalinger. Nordnet påtar seg ikke ansvar for kommentarene.
Nyheter og Analyser
Det er for øyeblikket ingen nyheter
Nyheter og/eller generelle investeringsanbefalinger, eller utdrag av disse på denne siden og øvrige lenker, er produsert og levert av den spesifiserte leverandøren. Nordnet har ikke deltatt i utarbeidelsen, og har ikke gjennomgått eller gjort endringer i materialet. Les mer om investeringsanbefalinger.
Kvartalsrapport (Q2)
5 dager siden
Nyheter og Analyser
Det er for øyeblikket ingen nyheter
Nyheter og/eller generelle investeringsanbefalinger, eller utdrag av disse på denne siden og øvrige lenker, er produsert og levert av den spesifiserte leverandøren. Nordnet har ikke deltatt i utarbeidelsen, og har ikke gjennomgått eller gjort endringer i materialet. Les mer om investeringsanbefalinger.
Shareville
Bli med i samtalen på SharevilleEt fellesskap av investorer som deler innsikt og kunnskap i sine porteføljer.
Logg inn
- 4. aug.4. aug.🚀🚀🚀🚀🚀🚀🚀🚀 NEW YORK, Aug. 4, 2025 /CNW/ -- As America's population ages, chronic and rare diseases are emerging as a pressing healthcare challenge — one that disproportionately affects older adults. With more than 30 million Americans living with a rare disease, the need for accurate diagnoses and effective treatments is growing urgent. Many of these conditions remain without FDA-approved therapies, and symptoms in seniors are often misattributed to typical aging, leading to years-long diagnostic delays. Recognizing this crisis, the Trump administration's "Make America Healthy Again" initiatives have emphasized improving access to treatments and accelerating medical innovation. Advancing this mission, Soligenix Inc. (NASDAQ: SNGX) (Profile) is making strides with its HyBryte(TM) platform, a novel therapy aimed at treating cutaneous T-cell lymphoma (CTCL), a rare skin cancer that primarily affects older adults. With successful U.S.-based manufacturing of HyBryte's active ingredient now in place, Soligenix exemplifies the kind of domestic innovation poised to make a meaningful impact on this underserved patient population. The company is one of several impressive companies committed to making an impact in the pharmaceutical space,
- 30. jan.30. jan.January 14 Soligenix announced an interim update on the open-label, investigator-initiated study evaluating extended HyBryte – synthetic hypericin – treatment for up to 12 months in patients with early-stage cutaneous T-cell lymphoma, or CTCL. To date, nine patients have been enrolled and treated with HyBryte over a time period of up to 54 weeks. Patients have responded positively to HyBryte therapy, with over 70% already achieving “Treatment Success”, predefined as a greater than or equal to 50% improvement in the cumulative mCAILS score compared to Baseline. Of the five Treatment Successes, three were achieved within the first 12 weeks of treatment, with two patients achieving a “complete response” by 18 weeks. In addition, HyBryte appears to be safe and well tolerated in all patients. Dr. Kim, Lead Investigator of the FLASH2 study, stated, “In the first Phase 3 FLASH study, HyBryte was shown to be efficacious with a benign safety profile compared to the current therapies of steroids, chemotherapeutics and ultraviolet light in this chronic orphan disease…In our FDA-funded study, initial results evaluating the expanded use of HyBryte in a “real world” treatment setting remain very promising, further supporting and extending results from the previous positive Phase 2 and 3 clinical trials. We look forward to continuing to work with the FDA to complete this study while we participate in the confirmatory Phase 3 placebo-controlled FLASH2 study.”
- 29. jan.29. jan.These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Phio Pharmaceuticals (PHIO), 39,675% surge in interest Eterna Therapeutics (ERNA), 11,117% surge in interest Salarius Pharmaceuticals (SLRX), 10,853% surge in interest Kairos Pharma (KAPA), 2,805% surge in interest Soligenix (SNGX), 1,913% surge in interest Silexion Therapeutics (SLXN), 1,717% surge in interest Azitra (AZTR), 1,645% surge in interest Black Diamond Therapeutics (BDTX), 1,315% surge in interest iBio (IBIO), 935% surge in interest GT Biopharma (GTBP), 900% surge in interest
Kommentarene ovenfor kommer fra brukere på Nordnets sosiale nettverk Shareville og er verken redigert eller forhåndsvist av Nordnet. De innebærer ikke at Nordnet gir investeringsråd eller investeringsanbefalinger. Nordnet påtar seg ikke ansvar for kommentarene.
Ordredybde
Antall
Kjøp
386
Selg
Antall
53
Siste handler
| Tid | Pris | Antall | Kjøpere | Selger |
|---|---|---|---|---|
| - | - | - | - |
Høy
4,3VWAP
Lav
3,46OmsetningAntall
8,4 4 212 237
VWAP
Høy
4,3Lav
3,46OmsetningAntall
8,4 4 212 237
Meglerstatistikk
Fant ingen data
Kunder besøkte også
Selskapshendelser
| Kommende | |
|---|---|
Selskapskalender ikke tilgjengelig | |
| Historisk | ||
|---|---|---|
| 2025 Kvartalsrapport (Q2) | 14. aug. | |
| 2025 Generalforsamling | 20. juni | |
| 2025 Kvartalsrapport (Q1) | 9. mai | |
| 2025 Kvartalsrapport (Q1) | 8. mai | |
| 2024 Kvartalsrapport (Q4) | 21. mars |
Data hentes fra Morningstar, Quartr
Kvartalsrapport (Q2)
5 dager siden
Nyheter og Analyser
Det er for øyeblikket ingen nyheter
Nyheter og/eller generelle investeringsanbefalinger, eller utdrag av disse på denne siden og øvrige lenker, er produsert og levert av den spesifiserte leverandøren. Nordnet har ikke deltatt i utarbeidelsen, og har ikke gjennomgått eller gjort endringer i materialet. Les mer om investeringsanbefalinger.
Selskapshendelser
| Kommende | |
|---|---|
Selskapskalender ikke tilgjengelig | |
| Historisk | ||
|---|---|---|
| 2025 Kvartalsrapport (Q2) | 14. aug. | |
| 2025 Generalforsamling | 20. juni | |
| 2025 Kvartalsrapport (Q1) | 9. mai | |
| 2025 Kvartalsrapport (Q1) | 8. mai | |
| 2024 Kvartalsrapport (Q4) | 21. mars |
Data hentes fra Morningstar, Quartr
Shareville
Bli med i samtalen på SharevilleEt fellesskap av investorer som deler innsikt og kunnskap i sine porteføljer.
Logg inn
- 4. aug.4. aug.🚀🚀🚀🚀🚀🚀🚀🚀 NEW YORK, Aug. 4, 2025 /CNW/ -- As America's population ages, chronic and rare diseases are emerging as a pressing healthcare challenge — one that disproportionately affects older adults. With more than 30 million Americans living with a rare disease, the need for accurate diagnoses and effective treatments is growing urgent. Many of these conditions remain without FDA-approved therapies, and symptoms in seniors are often misattributed to typical aging, leading to years-long diagnostic delays. Recognizing this crisis, the Trump administration's "Make America Healthy Again" initiatives have emphasized improving access to treatments and accelerating medical innovation. Advancing this mission, Soligenix Inc. (NASDAQ: SNGX) (Profile) is making strides with its HyBryte(TM) platform, a novel therapy aimed at treating cutaneous T-cell lymphoma (CTCL), a rare skin cancer that primarily affects older adults. With successful U.S.-based manufacturing of HyBryte's active ingredient now in place, Soligenix exemplifies the kind of domestic innovation poised to make a meaningful impact on this underserved patient population. The company is one of several impressive companies committed to making an impact in the pharmaceutical space,
- 30. jan.30. jan.January 14 Soligenix announced an interim update on the open-label, investigator-initiated study evaluating extended HyBryte – synthetic hypericin – treatment for up to 12 months in patients with early-stage cutaneous T-cell lymphoma, or CTCL. To date, nine patients have been enrolled and treated with HyBryte over a time period of up to 54 weeks. Patients have responded positively to HyBryte therapy, with over 70% already achieving “Treatment Success”, predefined as a greater than or equal to 50% improvement in the cumulative mCAILS score compared to Baseline. Of the five Treatment Successes, three were achieved within the first 12 weeks of treatment, with two patients achieving a “complete response” by 18 weeks. In addition, HyBryte appears to be safe and well tolerated in all patients. Dr. Kim, Lead Investigator of the FLASH2 study, stated, “In the first Phase 3 FLASH study, HyBryte was shown to be efficacious with a benign safety profile compared to the current therapies of steroids, chemotherapeutics and ultraviolet light in this chronic orphan disease…In our FDA-funded study, initial results evaluating the expanded use of HyBryte in a “real world” treatment setting remain very promising, further supporting and extending results from the previous positive Phase 2 and 3 clinical trials. We look forward to continuing to work with the FDA to complete this study while we participate in the confirmatory Phase 3 placebo-controlled FLASH2 study.”
- 29. jan.29. jan.These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Phio Pharmaceuticals (PHIO), 39,675% surge in interest Eterna Therapeutics (ERNA), 11,117% surge in interest Salarius Pharmaceuticals (SLRX), 10,853% surge in interest Kairos Pharma (KAPA), 2,805% surge in interest Soligenix (SNGX), 1,913% surge in interest Silexion Therapeutics (SLXN), 1,717% surge in interest Azitra (AZTR), 1,645% surge in interest Black Diamond Therapeutics (BDTX), 1,315% surge in interest iBio (IBIO), 935% surge in interest GT Biopharma (GTBP), 900% surge in interest
Kommentarene ovenfor kommer fra brukere på Nordnets sosiale nettverk Shareville og er verken redigert eller forhåndsvist av Nordnet. De innebærer ikke at Nordnet gir investeringsråd eller investeringsanbefalinger. Nordnet påtar seg ikke ansvar for kommentarene.
Ordredybde
Antall
Kjøp
386
Selg
Antall
53
Siste handler
| Tid | Pris | Antall | Kjøpere | Selger |
|---|---|---|---|---|
| - | - | - | - |
Høy
4,3VWAP
Lav
3,46OmsetningAntall
8,4 4 212 237
VWAP
Høy
4,3Lav
3,46OmsetningAntall
8,4 4 212 237
Meglerstatistikk
Fant ingen data